ICICI Direct has given Hold recommendation for Lupin with a target price of Rs. 1025 in its research report issued on Aug 12, 2021

ICICI Direct’s research report on Lupin

Lupin is a multinational pharma company engaged in manufacturing & marketing branded & generic formulations, APIs, biotech products as well as OTC medicines across multiple dosage forms & therapeutic categories. It is the third largest generic player (by prescriptions) in the US with 168 generic products (market leader: 52 products; Top 3: 122 products) along with being sixth largest company in Indian pharmaceutical market Lupin is the largest manufacturer of anti-TB drugs in the world and enjoys global leadership in anti-TB & Cephalosporins

Outlook

We retain HOLD rating on the stock We value Lupin at Rs 1025 i.e. 22x P/E on FY23E EPS.

 

Leave a Reply

Your email address will not be published. Required fields are marked *